CRNX Crinetics Pharmaceuticals, Inc. - Common Stock
$84.77
株価 · 8月 19, 2026
ファンダメンタルズ（時点） 8月 3, 2026
52週レンジ
$29–$85
100% of range
アナリスト評価
HOLD
21 analysts
目標株価
$86
+1% upside
P/E (TTM)
-17.1
ROE
-43.0%
純利益率
-6046.2%
Crinetics Pharmaceuticals, Inc. - Common Stock について Wikipediaからの企業概要
Crinetics Pharmaceuticals is a global pharmaceutical company known for developing drugs for the treatment of endocrine-related diseases. It was founded by Scott Struthers, Frank Zhu, Ana Kusnetzow, and Stephen F. Betz in 2008 and is headquartered in San Diego, California. It went public on NASDAQ in 2018.
続きを読む
Crinetics Pharmaceuticals is a global pharmaceutical company known for developing drugs for the treatment of endocrine-related diseases. It was founded by Scott Struthers, Frank Zhu, Ana Kusnetzow, and Stephen F. Betz in 2008 and is headquartered in San Diego, California. It went public on NASDAQ in 2018.
In July 2026, Vertex Pharmaceuticals agreed to acquire the company for $10 billion.
History
Struthers, Zhu, Kusnetzow, and Betz founded Crinetics in 2008 after previously working together on a small molecule drug for the treatment of endometriosis at Neurocrine Biosciences.
Crinetics expanded into a larger laboratory in 2010. After receiving NIH grant funding, Crinetics moved into its second laboratory.
In 2011, Crinetics Pharmaceuticals competed for the Michelson Prize, a competition sponsored by the Found Animals Foundation to develop a low-cost, non-surgical method for sterilizing dogs and cats, which would later lead to the licensing of a molecule for the treatment of acromegaly in large breed dogs.
Crinetics first synthesized its lead drug candidate to treat acromegaly. The drug was named paltusotine, in 2016. Crinetics Pharmaceuticals went public with an IPO in 2018. It conducted Phase II trials for paltusotine from 2019 to 2020. It conducted Phase III trials for paltusotine from 2021 to 2024. After the drug succeeded in a second Phase III study, the FDA accepted the company's new drug application for paltusotine and the company announced it was planning for a 2025 launch for the drug. The FDA set a Prescription Drug User Fee Act for the drug on September 25, 2025.
In 2021, Crinetics, together with 5AM Ventures and Frazier Healthcare Partners, formed an independently operated new company, Radionetics Oncology, aimed to develop a deep pipeline of novel, targeted, nonpeptide radiopharmaceuticals for the treatment of a broad range of oncology indications.
Crinetics partnered with the veterinary medicine company Loyal to develop a pill to extend the lifespans of large dogs in 2023.
In 2024, Scott Struthers received the Ernst & Young Entrepreneur of the Year Award for his work with Crinetics. In 2024, Crinetics was reported to have patent activity in rare diseases, health technology, and addiction therapies.
In 2024, Radionetics formed a strategic relationship with Eli Lilly and Company to take forward Radionetics’ proprietary GPCR targeting small molecule radiopharmaceuticals. Under the terms of the agreement, Radionetics received a $140 million upfront cash payment. As part of the strategic agreement, Lilly obtained the exclusive right to acquire Radionetics upon conclusion of an exercise period for $1 billion.
Crinetics also established its first office outside the United States in Zug, Switzerland in 2024.
In 2025, Crinetics Pharmaceuticals plans to file an Investigational New Drug for an oral thyroid stimulating hormone receptor antagonist and its nonpeptide drug conjugate (CRN09682). A total of four development candidates are currently in IND-enabling studies, including a PTH antagonist (Hyperparathyrodism), non-peptide drug conjugate (NETs and SST2-expressing solid tumors), TSH antagonist (Graves’ disease & TED) and SST3 agonist (ADPKD).
In July 2026, Vertex Pharmaceuticals agreed to acquire Crinetics for $10 billion.
Treatments
Crinetics’ pipeline focuses on synthesizing novel molecules for rare endocrine diseases. It is most known for developing paltusotine, a drug designed to treat the hormonal disorder acromegaly. Paltusotine works by helping moderate elevated IGF-1 levels, which is the main symptom of acromegaly. Paltusotine has also been tested as a treatment for carcinoid syndrome.
Crinetics has also developed oral treatments for neuroendocrine tumors, hyperinsulism, and Cushing's disease. The company's drug for treating Cushing's disease, Atumeltnant (also known as CRN049894), works by reducing levels of ACTH.
The company's pipeline also includes an oral parathyroid hormone inhibitor program for hyperparathyroidism and treatments for thyroid eye disease, Graves' disease, and obesity. Additionally, Crinetics nonpeptide drug conjugates (NDCs) include CRN09682, which is a somatostatin receptor 2 (SST2) targeted drug. NDCs are a new technology developed in-house by Crinetics.
== References ==
出典: Wikipedia (英語), CC BY-SA 4.0 · Wikipediaで表示 ↗
CRNX 株価スナップショット 価格、時価総額、P/E、EPS、ROE、負債/資本、52週レンジ
株価
$84.77
時価総額
$8.10B
P/E (TTM)
-17.1
EPS（TTM）
$-4.95
収益（TTM）
$8M
配当利回り
—
ROE
-43.0%
負債/自己資本
—
52週レンジ
$29 – $85
CRNX 株価チャート 技術指標付きの日次 OHLCV — パン、ズーム、ビューのカスタマイズ
Configure
10年間のパフォーマンス 収益、純利益、利益率、EPSのトレンド
収益と純利益
$8M
2016-12-31
→
2025-12-31
EPS
$-4.95
2020-12-31
→
2025-12-31
フリーキャッシュフロー
$-384M
2018-12-31
→
2025-12-31
利益率
-6046.2%
バリュエーション P/E、P/S、P/B、EV/EBITDA比率 — 株は割高か割安か？
指標
5年トレンド
CRNX
競合中央値
P/E (TTM)
-17.1
47.9
P/S (TTM) (株価売上高倍率（TTM）)
1052.7
16.2
P/B (株価純資産倍率)
8.2
9.3
Price / FCF (株価FCF倍率)
-21.1
—
収益性 粗利益率、営業利益率、純利益率、ROE、ROA、ROIC
指標
5年トレンド
CRNX
競合中央値
Operating Margin (営業利益率)
-6714.8%
—
Net Profit Margin (純利益率)
-6046.2%
5.1%
ROA
-36.3%
0.81%
ROE
-43.0%
-15.3%
ROIC
-52.1%
—
財務健全性 負債、流動性、支払能力 — バランスシートの健全性
指標
5年トレンド
CRNX
競合中央値
Current Ratio (流動比率)
12.3
2.7
Quick Ratio (クイックレシオ)
12.1
—
成長 収益、EPS、純利益の成長率：前年比、3年CAGR、5年CAGR
指標
5年トレンド
CRNX
競合中央値
Revenue YoY (収益（前年比）)
640.7%
—
Revenue CAGR 3Y (収益（3年CAGR）)
17.6%
—
Revenue CAGR 5Y (収益（5年CAGR）)
155.3%
—
資本効率 総資産回転率、棚卸資産回転率、売掛金回転率
指標
5年トレンド
CRNX
競合中央値
CRNX アナリストコンセンサス 強気・弱気のアナリストの見解、12ヶ月の目標株価、アップサイド
保有
21 アナリスト
- 強い買い 3 14.3%
- 買い 4 19.0%
- 保有 14 66.7%
- 売り 0 0.0%
- 強い売り 0 0.0%
12ヶ月目標株価
10 アナリスト · 2026-08-13
中央値
$85.00
平均値
$85.50
← 全目標を下回る
$84.77
安値
$85.00
高値
$90.00
中央値ターゲット
$85.00
+0.3%
平均値ターゲット
$85.50
+0.9%
決算履歴 EPS実績 vs 予想、サプライズ%、達成率、次回決算日
平均サプライズ
-0.01%
| 期間 | EPS Actual | EPS 予想 | サプライズ |
|---|---|---|---|
| 2026年6月30日 | $-1.14 | $-1.23 | 0.09% |
| 2026年3月31日 | $-1.23 | $-1.26 | 0.03% |
| 2025年12月31日 | $-1.29 | $-1.39 | 0.10% |
| 2025年9月30日 | $-1.38 | $-1.28 | -0.10% |
| 2025年6月30日 | $-1.23 | $-1.12 | -0.11% |
| 2025年3月31日 | $-1.04 | $-0.96 | -0.08% |
同業他社比較（GICSサブインダストリー） 主要メトリクスとセクターピアの比較
| ティッカー | 時価総額 | P/E | 売上高 YoY | 純利益率 | ROE | 粗利益率 |
|---|---|---|---|---|---|---|
| CRNX | $4.45B | -9.4 | 640.7% | -6046.2% | -43.0% | — |
| CORT | $3.69B | 42.4 | 12.8% | 13.1% | 15.5% | — |
| ELAN | $11.25B | -48.1 | 6.2% | -4.9% | -3.5% | 55.0% |
| AXSM | $9.29B | -49.6 | 65.5% | -28.7% | -227.0% | — |
| LQDA | $3.01B | -43.1 | 1031.2% | -43.5% | -230.0% | — |
| BLTE | — | — | — | — | — | — |
| DFTX | $1.32B | -6.5 | 212.0% | — | -71.0% | — |
| LGND | $3.74B | 30.8 | 60.4% | 46.4% | 13.5% | — |
| AMRX | — | 57.3 | 8.1% | 2.4% | -80.0% | 36.9% |
| LLY | — | 46.8 | 44.7% | 31.7% | 101.2% | — |
完全なファンダメンタルズ 年次別全指標 — 損益計算書、貸借対照表、キャッシュフロー
損益計算書 17
| 指標 | トレンド | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $8M | $1M | $4M | $5M | $1M | $71.0K | $1M | $2M | $2M | |
| Cost of Revenue | $1M | $0 | $0 | · | · | · | · | · | · | |
| R&D Expense | $332M | $240M | $169M | $130M | $84M | $57M | $42M | $24M | $9M | |
| SG&A Expense | $191M | $100M | $58M | $42M | $25M | $18M | $14M | $7M | $2M | |
| Operating Expenses | $524M | $340M | $227M | $173M | $109M | $75M | $55M | $31M | $11M | |
| Operating Income | $-517M | $-339M | $-223M | $-168M | $-108M | $-75M | $-54M | $-29M | $-9M | |
| Interest Expense | · | · | · | · | · | · | · | · | $8.0K | |
| Interest Income | $52M | $41M | $13M | $4M | $157.0K | $991.0K | $3M | $2M | $26.0K | |
| Other Non-op | $-357.0K | $-519.0K | $-159.0K | $5M | $61.0K | $1M | $3M | $2M | $-30.0K | |
| Pretax Income | $-465M | $-298M | $-209M | $-164M | $-108M | $-74M | $-50M | $-27M | $-9M | |
| Income Tax | $180.0K | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| Net Income | $-465M | $-298M | $-215M | $-164M | $-108M | $-74M | $-50M | $-27M | $-9M | |
| EPS (Basic) | $-4.95 | $-3.69 | $-3.69 | $-3.15 | $-2.80 | $-2.42 | · | · | · | |
| EPS (Diluted) | $-4.95 | $-3.69 | $-3.69 | $-3.15 | $-2.80 | $-2.42 | · | · | · | |
| Shares (Basic) | 94,057,000 | 80,783,000 | 58,071,000 | 51,982,000 | 38,436,000 | 30,448,000 | · | · | · | |
| Shares (Diluted) | 94,057,000 | 80,783,000 | 58,071,000 | 51,982,000 | 38,436,000 | 30,448,000 | · | · | · | |
| EBITDA | $-513M | $-339M | $-223M | $-168M | $-108M | $-75M | $-54M | $-29M | · |
貸借対照表 24
| 指標 | トレンド | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $102M | $265M | $55M | $33M | $201M | $93M | $40M | $45M | $14M | |
| Short-term Investments | $926M | $1.09B | $504M | $302M | $133M | $78M | $78M | $119M | · | |
| Receivables | $592.0K | $0 | · | · | · | · | · | · | · | |
| Inventory | $2M | $0 | · | · | · | · | · | · | · | |
| Prepaid Expense | $18M | $21M | $16M | $11M | $11M | $7M | $5M | $3M | $973.0K | |
| Other Current Assets | $3M | $2M | $448.0K | $2M | $912.0K | $1M | $668.0K | $876.0K | $239.0K | |
| Current Assets | $1.05B | $1.38B | $574M | $345M | $345M | $177M | $123M | $167M | $15M | |
| PP&E (Net) | $14M | $12M | $11M | $4M | $3M | $3M | $4M | $4M | $400.0K | |
| PP&E (Gross) | $22M | $20M | $16M | $8M | $6M | $6M | $6M | $5M | $704.0K | |
| Accum. Depreciation | $8M | $8M | $5M | $4M | $3M | $3M | $2M | $741.0K | $304.0K | |
| Other Non-current Assets | · | $3M | $2M | $37.0K | $0 | $40.0K | $82.0K | · | $33.0K | |
| Total Assets | $1.13B | $1.43B | $635M | $352M | $351M | $183M | $130M | $171M | $16M | |
| Accounts Payable | $23M | $6M | $7M | $7M | $3M | $6M | $5M | $5M | $403.0K | |
| Accrued Liabilities | · | · | · | · | · | · | · | $4M | $179.0K | |
| Current Liabilities | $85M | $60M | $44M | $28M | $16M | $10M | $8M | $8M | $897.0K | |
| Capital Leases | $42M | $45M | $48M | $2M | $3M | $4M | $5M | · | · | |
| Other Non-current Liabilities | $3M | $829.0K | $0 | · | · | · | · | · | · | |
| Total Liabilities | $134M | $110M | $96M | $36M | $19M | $15M | $13M | $11M | $920.0K | |
| Common Stock | · | · | $253.0K | $0 | · | · | · | $24.0K | $1.0K | |
| Retained Earnings | $-1.42B | $-952M | $-654M | $-439M | $-275M | $-168M | $-94M | $-43M | $-16M | |
| AOCI | $2M | $963.0K | $977.0K | $-4M | $-382.0K | $25.0K | $148.0K | $61.0K | · | |
| Stockholders' Equity | $992M | $1.32B | $539M | $316M | $332M | $169M | $117M | $160M | $-15M | |
| Liabilities + Equity | $1.13B | $1.43B | $635M | $352M | $351M | $183M | $130M | $171M | $16M | |
| Shares Outstanding | 95,575,000 | 92,926,000 | 68,175,000 | 53,877,000 | 47,597,000 | 33,001,000 | 24,263,000 | 24,061 | 1,549,575 |
キャッシュフロー 13
| 指標 | トレンド | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $4M | $3M | $1M | $983.0K | $922.0K | $948.0K | $887.0K | $471.0K | $128.0K | |
| Stock-based Comp | $91M | $69M | $41M | $28M | $17M | $10M | $6M | $2M | $271.0K | |
| Deferred Tax | $0 | $0 | $0 | · | · | · | · | · | · | |
| Other Non-cash | $-8M | · | · | · | · | · | · | · | · | |
| Operating Cash Flow | $-378M | $-230M | $-169M | $-115M | $-89M | $-62M | $-46M | $-19M | $-9M | |
| CapEx | $6M | $4M | $5M | $2M | $436.0K | $186.0K | $492.0K | $1M | $304.0K | |
| Investing Cash Flow | $174M | $-575M | $-200M | $-174M | $-56M | $217.0K | $42M | $-119M | $-304.0K | |
| Stock Issued | $0 | $985M | $370M | $117M | $250M | $114M | · | $106M | · | |
| Net Stock Activity | $0 | $970M | $369M | $117M | $250M | $114M | · | · | · | |
| Financing Cash Flow | $41M | $1.01B | $391M | $122M | $253M | $115M | $67.0K | $170M | $12M | |
| Net Change in Cash | · | $210M | $22M | $-167M | $108M | $53M | $-5M | $31M | $2M | |
| Taxes Paid | $89.0K | $0 | $0 | · | · | · | · | · | · | |
| Free Cash Flow | $-384M | $-230M | $-171M | $-117M | $-89M | $-62M | $-47M | $-21M | · |
収益性 7
| 指標 | トレンド | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -6714.8% | -32613.5% | -5547.2% | -3544.1% | -9990.9% | -105567.6% | -4512.3% | -1182.5% | · | |
| Net Margin | -6046.2% | -28720.7% | -5345.9% | -3460.4% | -9985.2% | -103960.6% | -4226.5% | -1116.8% | · | |
| Pretax Margin | -6043.9% | -28720.7% | -5345.9% | -3460.4% | -9985.2% | -103960.6% | -4226.5% | -1116.8% | · | |
| EBITDA Margin | -6664.1% | -32613.5% | -5547.2% | -3544.1% | -9990.9% | -105567.6% | -4512.3% | -1182.5% | · | |
| ROA | -36.3% | -28.8% | -43.5% | -46.6% | -40.3% | -47.0% | -33.4% | -29.0% | · | |
| ROE | -43.0% | -27.7% | -39.5% | -49.1% | -41.0% | -41.4% | -40.9% | -16.6% | · | |
| ROIC | -52.1% | -25.6% | -41.3% | -53.1% | -32.5% | -44.4% | -46.0% | -17.9% | · |
流動性と支払能力 2
| 指標 | トレンド | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 12.3 | 23.0 | 13.1 | 12.5 | 21.6 | 16.9 | 14.8 | 21.0 | · | |
| Quick Ratio | 12.1 | 22.7 | 12.7 | 12.1 | 20.9 | 16.3 | 14.2 | 20.7 | · |
効率性 3
| 指標 | トレンド | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | · | |
| Inventory Turnover | 1.1 | · | · | · | · | · | · | · | · | |
| Receivables Turnover | 26.0 | · | · | · | · | · | · | · | · |
成長率 3
| 指標 | トレンド | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 640.7% | -74.1% | -15.3% | 339.4% | 1418.3% | · | · | · | · | |
| Revenue CAGR 3Y | 17.6% | -1.2% | 283.8% | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 155.3% | · | · | · | · | · | · | · | · |
バリュエーション（TTM） 10
| 指標 | トレンド | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $8M | $1M | $4M | $5M | $1M | $71.0K | $1M | $2M | · | |
| Net Income TTM | $-465M | $-298M | $-215M | $-164M | $-108M | $-74M | $-50M | $-27M | · | |
| Market Cap | $4.45B | $4.75B | $2.43B | $986M | $1.35B | $466M | $608.8K | $722M | · | |
| P/E | -9.4 | -13.9 | -9.6 | -5.8 | -10.1 | -5.8 | · | · | · | |
| P/S | 578.1 | 4573.0 | 604.5 | 208.1 | 1254.4 | 6558.4 | 0.5 | 297.2 | · | |
| P/B | 4.5 | 3.6 | 4.5 | 3.1 | 4.1 | 2.8 | 0.0 | 4.5 | · | |
| P / Tangible Book | 4.5 | 3.6 | 4.5 | 3.1 | 4.1 | 2.8 | · | · | · | |
| P / Cash Flow | -11.8 | -21.0 | -14.6 | -8.6 | -15.3 | -7.5 | -0.0 | -37.1 | · | |
| P / FCF | -11.6 | -20.7 | -14.2 | -8.4 | -15.2 | -7.5 | -0.0 | -35.2 | · | |
| Earnings Yield | -10.6% | -7.2% | -10.4% | -17.2% | -9.9% | -17.2% | · | · | · |
損益計算書 15
| 指標 | トレンド | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $25M | $11M | $6M | $143.0K | $1M | $361.0K | $0 | $0 | $399.0K | $640.0K | $0 | $346.0K | $988.0K | $3M | $709.0K | $458.0K | |
| Cost of Revenue | $154.0K | $200.0K | · | · | $0 | $0 | · | · | · | · | · | · | · | · | · | · | |
| R&D Expense | $100M | $100M | $85M | $90M | $80M | $76M | $67M | $62M | $58M | $53M | $46M | $44M | $41M | $38M | $37M | $32M | |
| SG&A Expense | $58M | $51M | $54M | $52M | $50M | $36M | $28M | $26M | $25M | $21M | $17M | $15M | $13M | $12M | $11M | $12M | |
| Operating Expenses | $158M | $151M | $140M | $143M | $130M | $112M | $95M | $88M | $83M | $74M | $63M | $59M | $54M | $51M | $48M | $44M | |
| Operating Income | $-132M | $-140M | $-134M | $-143M | $-129M | $-111M | $-95M | $-88M | $-83M | $-74M | $-63M | $-59M | $-53M | $-48M | $-48M | $-43M | |
| Interest Income | $12M | $13M | $11M | $13M | $13M | $15M | $14M | $11M | $9M | $7M | $7M | $3M | $2M | $2M | $2M | $2M | |
| Other Non-op | $-423.0K | $-131.0K | $-28M | $-49.0K | $20.0K | $-203.0K | $-16M | $-37.0K | $9M | $7M | $-7M | $3M | $2M | $2M | $3M | $2M | |
| Pretax Income | · | · | $-123M | $-130M | · | · | $-81M | $-77M | · | · | · | · | · | · | · | · | |
| Net Income | $-121M | $-128M | $-123M | $-130M | $-116M | $-97M | $-81M | $-77M | $-74M | $-67M | $-60M | $-57M | $-51M | $-46M | $-45M | $-42M | |
| EPS (Basic) | $-1.14 | $-1.23 | $-1.30 | $-1.38 | $-1.23 | $-1.04 | $-0.86 | $-0.96 | $-0.94 | $-0.93 | $-0.89 | $-1.01 | $-0.94 | $-0.85 | $-0.83 | $-0.78 | |
| EPS (Diluted) | $-1.14 | $-1.23 | $-1.30 | $-1.38 | $-1.23 | $-1.04 | $-0.86 | $-0.96 | $-0.94 | $-0.93 | $-0.89 | $-1.01 | $-0.94 | $-0.85 | $-0.83 | $-0.78 | |
| Shares (Basic) | 105,560,000 | 104,099,000 | -187,051,000 | 94,215,000 | 93,791,000 | 93,102,000 | -150,605,000 | 80,091,000 | 79,008,000 | 72,289,000 | -106,920,000 | 56,808,000 | 54,275,000 | 53,908,000 | -102,020,000 | 53,768,000 | |
| Shares (Diluted) | 105,560,000 | 104,099,000 | -187,051,000 | 94,215,000 | 93,791,000 | 93,102,000 | -150,605,000 | 80,091,000 | 79,008,000 | 72,289,000 | -106,920,000 | 56,808,000 | 54,275,000 | 53,908,000 | -102,020,000 | 53,768,000 | |
| EBITDA | $-132M | $-140M | · | $-143M | $-129M | $-111M | · | $-88M | $-83M | $-74M | · | $-59M | $-53M | $-48M | · | $-43M |
貸借対照表 23
| 指標 | トレンド | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $55M | $114M | $102M | $111M | $54M | $95M | $265M | $317M | $302M | $396M | $55M | $143M | $40M | $41M | $33M | $31M | |
| Short-term Investments | $1.15B | $1.18B | $926M | $981M | $1.14B | $1.18B | $1.09B | $545M | $561M | $505M | · | $412M | $225M | $255M | · | $337M | |
| Receivables | $12M | $6M | $592.0K | · | · | · | $0 | · | · | · | · | · | · | · | · | · | |
| Inventory | $3M | $3M | $2M | · | · | · | $0 | · | · | · | · | · | · | · | · | · | |
| Prepaid Expense | $23M | $22M | $18M | $28M | $20M | $16M | $21M | $15M | $12M | $16M | · | $21M | $20M | $9M | · | $10M | |
| Other Current Assets | $5M | $6M | $3M | $5M | $4M | $3M | $2M | $1M | $2M | $4M | · | $4M | $3M | $3M | · | $2M | |
| Current Assets | $1.24B | $1.32B | $1.05B | $1.12B | $1.22B | $1.29B | $1.38B | $878M | $875M | $917M | · | $576M | $285M | $305M | · | $378M | |
| PP&E (Net) | $13M | $13M | $14M | $14M | $15M | $13M | $12M | $12M | $12M | $12M | · | $10M | $3M | $3M | · | $4M | |
| PP&E (Gross) | $23M | $23M | $22M | $21M | $24M | $21M | $20M | $19M | $18M | $17M | · | $15M | $8M | $8M | · | $7M | |
| Accum. Depreciation | $10M | $9M | $8M | $7M | $10M | $9M | $8M | $7M | $6M | $5M | · | $5M | $5M | $4M | · | $4M | |
| Other Non-current Assets | · | · | · | · | · | $14M | · | $3M | $2M | $2M | · | $2M | $2M | $2M | · | · | |
| Total Assets | $1.32B | $1.40B | $1.13B | $1.20B | $1.29B | $1.36B | $1.43B | $937M | $936M | $978M | · | $642M | $293M | $314M | · | $385M | |
| Accounts Payable | $13M | $13M | $23M | $6M | $11M | $10M | $6M | $5M | $9M | $11M | · | $6M | $5M | $6M | · | $6M | |
| Current Liabilities | $80M | $71M | $85M | $74M | $68M | $57M | $60M | $54M | $54M | $52M | · | $40M | $33M | $26M | · | $25M | |
| Capital Leases | $41M | $41M | $42M | $43M | $43M | $44M | $45M | $45M | $46M | $47M | · | $48M | $1M | $2M | · | $2M | |
| Other Non-current Liabilities | $6M | $5M | $3M | $3M | $2M | $2M | $829.0K | $511.0K | $202.0K | · | · | · | · | · | · | · | |
| Total Liabilities | $130M | $121M | $134M | $124M | $118M | $107M | $110M | $104M | $105M | $103M | · | $94M | $39M | $34M | · | $34M | |
| Common Stock | · | · | · | · | · | · | · | · | · | $881.0K | · | · | · | · | · | · | |
| Retained Earnings | $-1.67B | $-1.55B | $-1.42B | $-1.29B | $-1.16B | $-1.05B | $-952M | $-872M | $-795M | $-721M | · | $-594M | $-536M | $-485M | · | $-394M | |
| AOCI | $-3M | $-1M | $2M | $2M | $2M | $2M | $963.0K | $2M | $-190.0K | $150.0K | · | $-865.0K | $-2M | $-3M | · | $-5M | |
| Stockholders' Equity | $1.19B | $1.28B | $992M | $1.07B | $1.17B | $1.25B | $1.32B | $833M | $831M | $875M | $539M | $548M | $254M | $280M | $316M | $351M | |
| Liabilities + Equity | $1.32B | $1.40B | $1.13B | $1.20B | $1.29B | $1.36B | $1.43B | $937M | $936M | $978M | · | $642M | $293M | $314M | · | $385M | |
| Shares Outstanding | 105,808,000 | 105,314,000 | 95,575,000 | 94,548,000 | 94,126,000 | 93,525,000 | 92,926,000 | 80,841,000 | 79,322,000 | 78,539,000 | · | 66,708,000 | 54,682,000 | 53,990,000 | · | 53,796,000 |
キャッシュフロー 10
| 指標 | トレンド | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $1M | $1M | $994.0K | $1M | $959.0K | $925.0K | $788.0K | $770.0K | $753.0K | $474.0K | $262.0K | $273.0K | $280.0K | $283.0K | $280.0K | $248.0K | |
| Stock-based Comp | $25M | $30M | $22M | $23M | $26M | $20M | $19M | $18M | $19M | $13M | $12M | $11M | $10M | $8M | $8M | $7M | |
| Operating Cash Flow | $-94M | $-125M | $-93M | $-111M | $-86M | $-88M | $-67M | $-65M | $-48M | $-53M | $-41M | $-41M | $-46M | $-41M | $-35M | $-38M | |
| CapEx | $521.0K | $820.0K | $458.0K | $863.0K | $3M | $1M | $1M | $528.0K | $955.0K | $1M | $935.0K | $4M | $237.0K | $16.0K | $274.0K | $682.0K | |
| Investing Cash Flow | $26M | $-252M | $57M | $165M | $38M | $-86M | $-542M | $21M | $-54M | $309.0K | $-87M | $-193M | $31M | $49M | $37M | $7M | |
| Stock Issued | $0 | $381M | $0 | $0 | $0 | $0 | $544M | $63M | $10M | $383M | $29M | $329M | $11M | $0 | $0 | $-13.0K | |
| Net Stock Activity | · | $381M | · | · | · | $0 | · | · | · | $383M | · | · | · | · | · | · | |
| Financing Cash Flow | $9M | $390M | $26M | $3M | $7M | $4M | $556M | $59M | $8M | $394M | $40M | $338M | $13M | $484.0K | $115.0K | $1M | |
| Net Change in Cash | · | · | · | $57M | $-41M | $-170M | · | $15M | $-94M | $341M | · | $103M | $-2M | $9M | $2M | $-31M | |
| Free Cash Flow | · | $-126M | · | · | · | $-90M | · | · | · | $-54M | · | · | · | $-41M | · | · |
収益性 6
| 指標 | トレンド | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -527.4% | -1307.8% | · | -99710.5% | -12523.0% | -30860.1% | · | · | -20747.6% | -11488.9% | · | -17045.4% | -5363.9% | -1790.9% | · | -9487.8% | |
| Net Margin | -481.1% | -1191.0% | · | -90972.7% | -11216.0% | -26807.2% | · | · | -18560.1% | -10457.8% | · | -16606.4% | -5159.8% | -1716.9% | · | -9153.9% | |
| Pretax Margin | · | · | · | -90972.7% | · | · | · | · | · | · | · | · | · | · | · | · | |
| EBITDA Margin | -527.4% | -1307.8% | · | -99710.5% | -12523.0% | -30860.1% | · | · | -20747.6% | -11488.9% | · | -17045.4% | -5363.9% | -1790.9% | · | -9487.8% | |
| ROA | -9.3% | -9.3% | · | -12.2% | -10.4% | -8.3% | · | -9.7% | -12.0% | -10.4% | · | -11.2% | -14.3% | -14.2% | · | -14.1% | |
| ROE | -10.2% | -10.1% | · | -13.7% | -11.6% | -9.1% | · | -11.1% | -13.7% | -11.6% | · | -12.8% | -15.9% | -15.8% | · | -15.4% |
流動性と支払能力 2
| 指標 | トレンド | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 15.6 | 18.6 | · | 15.1 | 17.8 | 22.5 | · | 16.4 | 16.1 | 17.7 | · | 14.2 | 8.7 | 11.6 | · | 15.4 | |
| Quick Ratio | 15.2 | 18.2 | · | 14.7 | 17.5 | 22.2 | · | 16.1 | 15.9 | 17.4 | · | 13.7 | 8.1 | 11.3 | · | 15.0 |
効率性 3
| 指標 | トレンド | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | |
| Inventory Turnover | 0.1 | 0.1 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Receivables Turnover | 4.2 | 3.8 | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
バリュエーション（TTM） 10
| 指標 | トレンド | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $37M | $12M | · | $2M | $2M | $1M | · | $1M | $2M | $5M | · | $4M | $5M | $7M | · | $4M | |
| Net Income TTM | $-494M | $-470M | · | $-419M | $-363M | $-315M | · | $-275M | $-249M | $-221M | · | $-196M | $-181M | $-165M | · | $-147M | |
| Market Cap | $3.96B | $3.83B | · | $3.94B | $2.71B | $3.14B | · | $4.13B | $3.55B | $3.68B | · | $1.98B | $985M | $867M | · | $1.06B | |
| P/E | -7.5 | -7.4 | · | -9.0 | -6.9 | -8.7 | · | -13.3 | -11.7 | -12.5 | · | -8.3 | -5.3 | -5.1 | · | -6.4 | |
| P/S | 106.9 | 311.8 | · | 2565.4 | 1511.5 | 2240.6 | · | 2982.7 | 1497.2 | 790.1 | · | 443.7 | 215.9 | 129.3 | · | 262.3 | |
| P/B | 3.3 | 3.0 | · | 3.7 | 2.3 | 2.5 | · | 5.0 | 4.3 | 4.2 | · | 3.6 | 3.9 | 3.1 | · | 3.0 | |
| P / Tangible Book | 3.3 | 3.0 | · | 3.7 | 2.3 | 2.5 | · | 5.0 | 4.3 | 4.2 | · | 3.6 | 3.9 | 3.1 | · | 3.0 | |
| P / Cash Flow | · | -30.7 | · | · | · | -35.5 | · | · | · | -69.6 | · | · | · | -21.3 | · | · | |
| P / FCF | · | -30.5 | · | · | · | -35.0 | · | · | · | -67.8 | · | · | · | -21.3 | · | · | |
| Earnings Yield | -13.3% | -13.4% | · | -11.1% | -14.5% | -11.5% | · | -7.5% | -8.5% | -8.0% | · | -12.0% | -18.8% | -19.7% | · | -15.5% |
財務諸表 損益計算書、貸借対照表、キャッシュフロー — 年次、過去5年間
損益計算書
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 収益 | $8M | $1M | $4M | $5M | $1M |
| 営業利益率 % | -6714.8% | -32613.5% | -5547.2% | -3544.1% | -9990.9% |
| 純利益 | $-465M | $-298M | $-215M | $-164M | $-108M |
| 希薄化後EPS | $-4.95 | $-3.69 | $-3.69 | $-3.15 | $-2.80 |
貸借対照表
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 流動比率 | 12.3 | 23.0 | 13.1 | 12.5 | 21.6 |
| クイックレシオ | 12.1 | 22.7 | 12.7 | 12.1 | 20.9 |
キャッシュフロー
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| フリーキャッシュフロー | $-384M | $-230M | $-171M | $-117M | $-89M |
最新ニュース この会社に言及した最近の見出し
- Vertex to Acquire Crinetics Pharmaceuticals (CRNX) in $85 Per Share Cash Deal
- Does Vertex's Acquisition of Crinetics Pharmaceuticals Make the Stock a No-Brainer Buy?
- Vertex Pharmaceuticals Bets $10 Billion on Crinetics to Build Endocrinology Powerhouse
- Why This Pharmaceutical Stock Jumped Close to 100% This Week
- Crinetics Pharmaceuticals (CRNX) is One of the Best AI Driven Biotech Stocks, Here is Why
マイ指標 あなた専用のウォッチリスト — 決算詳細から選択した行
📊
あなたにとって重要なメトリクスを選択 — 上記の決算詳細の任意の行の横にある➕をクリックしてください。
選択内容は保存され、すべてのティッカーで引き継がれます。
機関投資家（13F） 286 提出者 · $3.2B合計 · 時点 2026年6月30日
四半期SECフォーム13Fでこの株式の保有を報告している機関。ロングポジションのみ。単一の提出者は、別々のオプションレッグで2回表示される場合があります。 大きな反対売買のプット/コール・レッグは、通常、マーケットメイクまたはヘッジされた在庫を反映しており、方向性への確信を示すものではありません。
機関投資家の動向 — Q2 2026 対 前四半期
| 新規ポジション | 解消済みポジション | 増加 | 減少 | 純株式数増減 |
|---|---|---|---|---|
| 63 (+17 前期比) | 30 (-14 前期比) | 95 (-17 前期比) | 63 (+3 前期比) | +21.6M |
Q1 2026と比較しました。 SECフォーム13Fの提出期限は四半期末から45日後ですが、遅延提出者向けの短いバッファーが含まれます。この期間内の四半期は、直近で完全に報告されたペアを優先するためスキップされます。
| 機関投資家 | 評価額 | 株式数 | % 追跡された13Fのうち | タイプ |
|---|---|---|---|---|
| FMR LLC | $486,250,673 | 12,994,406 | 15.13% | 株式数 |
| FARALLON CAPITAL MANAGEMENT, L.L.C. | $336,372,047 | 8,989,098 | 10.46% | 株式数 |
| Driehaus Capital Management LLC | $241,866,078 | 6,463,551 | 7.52% | 株式数 |
| WELLINGTON MANAGEMENT GROUP LLP | $237,002,526 | 6,333,579 | 7.37% | 株式数 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $180,836,416 | 4,832,614 | 5.63% | 株式数 |
| VANGUARD CAPITAL MANAGEMENT LLC | $177,567,704 | 4,745,262 | 5.52% | 株式数 |
| STATE STREET CORP | $100,635,477 | 2,689,350 | 3.13% | 株式数 |
| Bellevue Group AG | $98,040,400 | 2,620,000 | 3.05% | 株式数 |
| BAKER BROS. ADVISORS LP | $87,991,820 | 2,351,465 | 2.74% | 株式数 |
| GEODE CAPITAL MANAGEMENT, LLC | $87,542,675 | 2,338,905 | 2.72% | 株式数 |
| Polar Capital Holdings Plc | $85,108,460 | 2,274,411 | 2.65% | 株式数 |
| Pictet Asset Management Holding SA | $77,572,984 | 2,075,375 | 2.41% | 株式数 |
| Siren, L.L.C. | $53,165,887 | 1,420,788 | 1.65% | 株式数 |
| First Light Asset Management, LLC | $50,923,606 | 1,360,866 | 1.58% | 株式数 |
| NOVO HOLDINGS A/S | $49,394,400 | 1,320,000 | 1.54% | 株式数 |
| AMERICAN CENTURY COMPANIES INC | $47,245,129 | 1,262,562 | 1.47% | 株式数 |
| ADAR1 Capital Management, LLC | $45,730,234 | 1,222,080 | 1.42% | 株式数 |
| DIMENSIONAL FUND ADVISORS LP | $44,555,208 | 1,190,679 | 1.39% | 株式数 |
| MONTANOVA CAPITAL, LLC | $44,390,560 | 1,186,279 | 1.38% | 株式数 |
| ORBIMED ADVISORS LLC | $37,382,580 | 999,000 | 1.16% | 株式数 |
| Hood River Capital Management LLC | $36,259,830 | 968,996 | 1.13% | 株式数 |
| GOLDMAN SACHS GROUP INC | $34,657,132 | 926,166 | 1.08% | 株式数 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $32,841,401 | 877,643 | 1.02% | 株式数 |
| Aberdeen Group plc | $30,699,181 | 820,395 | 0.95% | 株式数 |
| Candriam S.C.A. | $30,618,690 | 819,032 | 0.95% | 株式数 |
| VANGUARD FIDUCIARY TRUST CO | $28,230,995 | 754,436 | 0.88% | 株式数 |
| Fisher Asset Management, LLC | $27,748,912 | 741,553 | 0.86% | 株式数 |
| SCHRODER INVESTMENT MANAGEMENT GROUP | $17,709,036 | 479,400 | 0.55% | 株式数 |
| AMERIPRISE FINANCIAL INC | $17,451,149 | 466,356 | 0.54% | 株式数 |
| Impax Asset Management Group plc | $16,277,700 | 435,000 | 0.51% | 株式数 |
| Prosight Management, LP | $14,020,002 | 374,666 | 0.44% | 株式数 |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $13,991,714 | 373,910 | 0.44% | 株式数 |
| KENNEDY CAPITAL MANAGEMENT LLC | $13,685,018 | 365,714 | 0.43% | 株式数 |
| BRAUN STACEY ASSOCIATES INC | $13,027,511 | 348,143 | 0.41% | 株式数 |
| Fiera Capital Corp | $12,395,263 | 331,247 | 0.39% | 株式数 |
| BANK OF AMERICA CORP /DE/ | $11,271,877 | 301,226 | 0.35% | 株式数 |
| Defilade Capital Management, L.P. | $8,959,845 | 239,440 | 0.28% | 株式数 |
| SEB Asset Management AB | $8,003,786 | 213,891 | 0.25% | 株式数 |
| Foresite Capital Management VI LLC | $7,933,414 | 212,010 | 0.25% | 株式数 |
| RICE HALL JAMES & ASSOCIATES, LLC | $7,346,220 | 196,318 | 0.23% | 株式数 |
| TD Asset Management Inc | $7,152,534 | 191,142 | 0.22% | 株式数 |
| Swiss National Bank | $6,877,796 | 183,800 | 0.21% | 株式数 |
| SEGALL BRYANT & HAMILL, LLC | $6,855,307 | 183,199 | 0.21% | 株式数 |
| BlackRock, Inc. | $6,781,290 | 181,221 | 0.21% | 株式数 |
| JENNISON ASSOCIATES LLC | $6,056,839 | 161,861 | 0.19% | 株式数 |
| New Leaf Venture Partners, L.L.C. | $5,872,650 | 141,000 | 0.18% | 株式数 |
| SILVERCREST ASSET MANAGEMENT GROUP LLC | $5,865,136 | 156,738 | 0.18% | 株式数 |
| Foresite Capital Management IV, LLC | $5,613,000 | 150,000 | 0.17% | 株式数 |
| Bank of New York Mellon Corp | $5,581,754 | 149,165 | 0.17% | 株式数 |
| NEW YORK STATE COMMON RETIREMENT FUND | $5,508,898 | 147,218 | 0.17% | 株式数 |
| ENVESTNET ASSET MANAGEMENT INC | $5,471,384 | 146,216 | 0.17% | 株式数 |
| Moody Aldrich Partners LLC | $5,466,201 | 146,077 | 0.17% | 株式数 |
| Ishara Investments LP | $5,369,770 | 143,500 | 0.17% | 株式数 |
| CITADEL ADVISORS LLC | $5,176,271 | 138,329 | 0.16% | 株式数 |
| RHUMBLINE ADVISERS | $4,861,141 | 129,908 | 0.15% | 株式数 |
| ALLIANCEBERNSTEIN L.P. | $4,782,618 | 131,680 | 0.15% | 株式数 |
| GordonMD Global Investments LP | $4,751,779 | 126,985 | 0.15% | 株式数 |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $4,712,974 | 125,948 | 0.15% | 株式数 |
| JANUS HENDERSON GROUP PLC | $4,700,428 | 129,392 | 0.15% | 株式数 |
| Cormorant Asset Management, LP | $4,677,500 | 125,000 | 0.15% | 株式数 |
| SECTOR GAMMA AS | $4,289,380 | 114,628 | 0.13% | 株式数 |
| XTX Topco Ltd | $4,164,547 | 111,292 | 0.13% | 株式数 |
| ALPS ADVISORS INC | $3,981,825 | 106,409 | 0.12% | 株式数 |
| FEDERATED HERMES, INC. | $3,957,390 | 105,756 | 0.12% | 株式数 |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $3,834,048 | 105,563 | 0.12% | 株式数 |
| Nuveen Asset Management, LLC | $3,760,151 | 73,541 | 0.12% | 株式数 |
| Burkehill Global Management, LP | $3,742,000 | 100,000 | 0.12% | 株式数 |
| Nuveen, LLC | $3,619,262 | 96,720 | 0.11% | 株式数 |
| VICTORY CAPITAL MANAGEMENT INC | $3,484,251 | 93,112 | 0.11% | 株式数 |
| MORGAN STANLEY | $3,320,829 | 88,744 | 0.10% | 株式数 |
| TWO SIGMA INVESTMENTS, LP | $3,266,729 | 87,299 | 0.10% | 株式数 |
| VANGUARD ASSET MANAGEMENT, Ltd | $3,254,754 | 86,979 | 0.10% | 株式数 |
| AWM Investment Company, Inc. | $3,180,700 | 85,000 | 0.10% | 株式数 |
| Odyssean, LLC | $3,160,344 | 84,456 | 0.10% | 株式数 |
| Affinity Asset Advisors, LLC | $2,806,500 | 75,000 | 0.09% | 株式数 |
| ALGERT GLOBAL LLC | $2,714,147 | 72,532 | 0.08% | 株式数 |
| ExodusPoint Capital Management, LP | $2,652,404 | 70,882 | 0.08% | 株式数 |
| Ensign Peak Advisors, Inc | $2,507,290 | 67,004 | 0.08% | 株式数 |
| BARCLAYS PLC | $2,466,127 | 65,904 | 0.08% | 株式数 |
| FIRST TRUST ADVISORS LP | $2,370,631 | 63,352 | 0.07% | 株式数 |
| Man Group plc | $2,284,229 | 61,043 | 0.07% | 株式数 |
| MetLife Investment Management, LLC | $2,258,709 | 60,361 | 0.07% | 株式数 |
| CITIGROUP INC | $2,255,229 | 60,268 | 0.07% | 株式数 |
| Longaeva Partners L.P. | $2,184,879 | 58,388 | 0.07% | 株式数 |
| Swedbank AB | $2,155,392 | 57,600 | 0.07% | 株式数 |
| STATE OF WISCONSIN INVESTMENT BOARD | $2,068,016 | 55,265 | 0.06% | 株式数 |
| Jump Financial, LLC | $1,923,388 | 51,400 | 0.06% | 株式数 |
| Lighthouse Investment Partners, LLC | $1,871,000 | 50,000 | 0.06% | 株式数 |
| Vestmark Advisory Solutions, Inc. | $1,823,252 | 48,724 | 0.06% | 株式数 |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | $1,787,254 | 47,762 | 0.06% | 株式数 |
| VANGUARD GROUP INC | $1,774,626 | 38,123 | 0.06% | 株式数 |
| Point72 Asset Management, L.P. | $1,735,577 | 46,381 | 0.05% | 株式数 |
| BNP PARIBAS FINANCIAL MARKETS | $1,696,398 | 45,334 | 0.05% | 株式数 |
| RAYMOND JAMES FINANCIAL INC | $1,606,254 | 42,925 | 0.05% | 株式数 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $1,549,188 | 41,400 | 0.05% | コールオプション |
| Invesco Ltd. | $1,545,446 | 41,300 | 0.05% | 株式数 |
| Vanguard Global Advisers, LLC | $1,485,986 | 39,711 | 0.05% | 株式数 |
| HighMark Wealth Management LLC | $1,444,224 | 38,595 | 0.04% | 株式数 |
| OAK RIDGE INVESTMENTS LLC | $1,405,046 | 37,548 | 0.04% | 株式数 |
| Orion Porfolio Solutions, LLC | $1,404,234 | 37,526 | 0.04% | 株式数 |
企業インサイダー 20 人のインサイダー · 9人の役員 · 10人の取締役
| インサイダー | 役職 | 最終アクティビティ | 保有株式数 | 12ヶ月購入 | 12ヶ月売却 | 12ヶ月純額 |
|---|---|---|---|---|---|---|
| Tobin Schilke | Chief Financial Officer | 2025年3月10日 A | 52,000 | 0 | 0 | $0 |
| Marc Wilson | CFO | 2024年9月26日 M | 111,092 | 0 | 0 | $0 |
| Jeff E. Knight | Chief Operating Officer | 2025年3月19日 S | 87,491 | 0 | 0 | $0 |
| Stephen F. Betz | Chief Scientific Officer | 2025年6月12日 M | 99,713 | 0 | 0 | $0 |
| Dana Pizzuti | Chief Med and Dev Officer | 2025年3月19日 S | 72,233 | 0 | 0 | $0 |
| Isabel Kalofonos | Chief Commercial Officer | 2025年1月10日 A | — | 0 | 0 | $0 |
| James Hassard | Chief Commercial Officer | 2024年7月5日 M | 29,259 | 0 | 0 | $0 |
| Alan Seth Krasner | Chief Medical Officer | 2023年10月17日 M | 43,210 | 0 | 0 | $0 |
| Ajay Madan | Chief Development Officer | 2022年2月28日 A | 176,995 | 0 | 0 | $0 |
| Coelho Rogerio Vivaldi | 取締役 | 2026年7月2日 S | 19,225 | 0 | 1 | $-120,000 |
| Caren Deardorf | 取締役 | 2026年6月18日 A | 22,225 | 0 | 0 | $0 |
| Weston Nichols | 取締役 | 2026年6月18日 A | 22,225 | 0 | 0 | $0 |
| Stephanie Okey | 取締役 | 2026年6月18日 A | 12,325 | 0 | 2 | $-246,143 |
| Matthew K Fust | 取締役 | 2026年6月18日 A | 28,761 | 0 | 0 | $0 |
| Camille L Bedrosian | 取締役 | 2026年6月18日 A | 22,225 | 0 | 0 | $0 |
| Wendell Wierenga | 取締役 | 2026年6月18日 A | 122,071 | 0 | 0 | $0 |
| Wendall Wierenga | 取締役 | 2025年6月11日 A | 116,146 | 0 | 0 | $0 |
| Stephen W Kaldor | 取締役 | 2020年6月19日 A | — | 0 | 0 | $0 |
| Jack Nielsen | 取締役 | 2019年6月21日 A | — | 0 | 0 | $0 |
| Richard Scott Struthers | — | 2026年8月7日 M | 424,706 | 0 | 0 | $0 |
SECフォーム3/4/5提出書類からのインサイダー；純額＝公開市場のP/Sのみ
アクティビストおよび5%超のオーナー 1保有
SECスケジュール13Dを提出した投資家 — 発行体の影響を与える意図（アクティビストの保有、取締役会キャンペーン、M&A）を持つ5%超の受益権所有。各行は、その提出者のポジションの最新の既知の状態を示します。
| 提出者 | 提出済み | 保有 | ステータス | 目的 | 提出書類 |
|---|---|---|---|---|---|
| Perceptive Advisors LLC, Joseph Edelman, Perceptive Life Sciences Master Fund, Ltd. ×6 提出書類 | 2024年3月1日 | — | 初回提出 | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ETF保有状況 55のETFが保有
ウェイトは直接株式保有（N-PORT）のみを反映しています。レバレッジ型またはデリバティブベースのファンドは、表示されていない追加のスワップエクスポージャーを保有している可能性があります。
| ファンド | ウェイト | 単位 | 時点 | ソース |
|---|---|---|---|---|
| SBIO · ALPS ETF Trust | 2.37% | 107,892 NS | 2026年5月31日 | N-PORT |
| IHE · iShares Trust | 1.95% | 376,636 SH | 2026年8月8日 | 日次 |
| FMED · Fidelity Covington Trust | 1.65% | 19,000 NS | 2026年5月31日 | N-PORT |
| PILL · Direxion Shares ETF Trust | 1.40% | 4,666 NS | 2026年4月30日 | N-PORT |
| BBP · ETFis Series Trust I | 1.23% | 18,743 NS | 2026年4月30日 | N-PORT |
| MMSC · First Trust Exchange-Traded Fund VI… | 0.75% | 11,043 NS | 2026年5月31日 | N-PORT |
| IBB · iShares Trust | 0.63% | 718,323 SH | 2026年8月8日 | 日次 |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0.60% | 5,737 SH | 2026年8月8日 | 日次 |
| IWO · iShares Trust | 0.54% | 940,202 SH | 2026年8月8日 | 日次 |
| NUSC · Nushares ETF Trust | 0.28% | 93,045 NS | 2026年4月30日 | N-PORT |
| ISCG · iShares Trust | 0.27% | 32,694 SH | 2026年8月8日 | 日次 |
| IWM · iShares Trust | 0.27% | 2,625,192 SH | 2026年8月8日 | 日次 |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0.23% | 110,770 SH | 2026年8月8日 | 日次 |
| BBSC · J.P. Morgan Exchange-Traded Fund Tr… | 0.20% | 38,553 NS | 2026年4月30日 | N-PORT |
| BIB · ProShares Trust | 0.19% | 3,872 NS | 2026年5月31日 | N-PORT |
| ESML · iShares Trust | 0.16% | 55,438 SH | 2026年8月8日 | 日次 |
| BKSE · BNY Mellon ETF Trust | 0.15% | 3,142 NS | 2026年4月30日 | N-PORT |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0.15% | 51,135 SH | 2026年8月8日 | 日次 |
| FNY · First Trust Exchange-Traded AlphaDE… | 0.14% | 18,879 NS | 2026年4月30日 | N-PORT |
| ISCB · iShares Trust | 0.13% | 4,625 SH | 2026年8月8日 | 日次 |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0.12% | 596,648 SH | 2026年8月8日 | 日次 |
| RSSL · Global X Funds | 0.12% | 42,391 NS | 2026年4月30日 | N-PORT |
| VBK · VANGUARD INDEX FUNDS | 0.11% | 1,399,667 SH | 2026年8月8日 | 日次 |
| FFSM · FIDELITY COVINGTON TRUST | 0.10% | 31,759 NS | 2026年4月30日 | N-PORT |
| ITWO · ProShares Trust | 0.09% | 4,601 NS | 2026年5月31日 | N-PORT |
| OMFS · Invesco Exchange-Traded Self-Indexe… | 0.09% | 2,909 SH | 2026年8月8日 | 日次 |
| SCHA · SCHWAB STRATEGIC TRUST | 0.08% | 492,431 NS | 2026年5月31日 | N-PORT |
| FNX · First Trust Exchange-Traded AlphaDE… | 0.07% | 24,991 NS | 2026年4月30日 | N-PORT |
| WSML · iShares Trust | 0.07% | 5,742 SH | 2026年8月8日 | 日次 |
| FHLC · FIDELITY COVINGTON TRUST | 0.06% | 41,183 NS | 2026年4月30日 | N-PORT |
| DFAS · Dimensional ETF Trust | 0.05% | 196,549 NS | 2026年4月30日 | N-PORT |
| UWM · ProShares Trust | 0.05% | 3,599 NS | 2026年5月31日 | N-PORT |
| VB · VANGUARD INDEX FUNDS | 0.05% | 2,419,186 SH | 2026年8月8日 | 日次 |
| VHT · VANGUARD WORLD FUND | 0.05% | 275,155 SH | 2026年8月8日 | 日次 |
| FAD · First Trust Exchange-Traded AlphaDE… | 0.04% | 5,196 NS | 2026年4月30日 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0.04% | 1,210,574 SH | 2026年8月8日 | 日次 |
| AVIE · AMERICAN CENTURY ETF TRUST | 0.04% | 112 NS | 2026年5月31日 | N-PORT |
| URTY · ProShares Trust | 0.04% | 3,643 NS | 2026年5月31日 | N-PORT |
| GSSC · Goldman Sachs ETF Trust | 0.02% | 5,689 NS | 2026年5月31日 | N-PORT |
| MSSM · MORGAN STANLEY PATHWAY FUNDS | 0.02% | 3,773 NS | 2026年5月31日 | N-PORT |
| HDG · ProShares Trust | 0.02% | 91 NS | 2026年5月31日 | N-PORT |
| ITOT · iShares Trust | 0.01% | 146,419 SH | 2026年8月8日 | 日次 |
| IWV · iShares Trust | 0.01% | 27,043 SH | 2026年8月8日 | 日次 |
| DFAC · Dimensional ETF Trust | 0.01% | 125,853 NS | 2026年4月30日 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0.01% | 3,342,704 SH | 2026年8月8日 | 日次 |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0.01% | 8,345 SH | 2026年8月8日 | 日次 |
| ESGV · VANGUARD WORLD FUND | 0.01% | 22,843 SH | 2026年8月8日 | 日次 |
| ONEQ · Fidelity Commonwealth Trust | 0.01% | 28,694 NS | 2026年5月31日 | N-PORT |
| DCOR · Dimensional ETF Trust | 0.01% | 5,863 NS | 2026年4月30日 | N-PORT |
| TILT · FlexShares Trust | 0.01% | 3,388 NS | 2026年4月30日 | N-PORT |